pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 96

Drugs Antibody Pharma Companies Development 96

Delveinsight

AUGUST 2, 2020

The company has also signed a licensing agreement with Ono Pharmaceutical , a Japanese pharma company, transferring exclusive rights to develop and commercialise anamorelin in Japan, South Korea, and Taiwan. Cancer Cachexia Pipeline. Apart from the products as mentioned earlier, Tetra Bio?

Marketing 94

Marketing Pharma Companies Development Hormones 94

Drug Discovery World

OCTOBER 4, 2022

Oligomerix’s portfolio of compounds is expected to provide a potentially lower-cost treatment alternative and/or complement to the newly emerging high-cost therapeutic options such as the monoclonal antibody products. Several of the large pharma companies have recently re-entered the dementia field. With its recent award of $3.35

Development 52

Development In-Vivo Compound Screening Clinical Development 52

pharmaphorum

SEPTEMBER 8, 2022

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). Last year, the company signed two deals in quick succession, which saw it form a licensing deal worth $1.3 The drug was added to Novartis’ portfolio through a $2.1

Manufacturing 104

Manufacturing Development Drugs Antibody 104

pharmaphorum

DECEMBER 23, 2020

There was some steady progress in neurology – in February FDA approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. months, compared with 6.7

Marketing 80

Marketing Gene Silencing Gene Drugs 80

Delveinsight

AUGUST 17, 2020

million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence. However, the drug is not FDA-approved but is available in some European countries.

Marketing 54

Marketing FDA Approval Trials Clinical Development 54

Delveinsight

NOVEMBER 29, 2020

Key players such as Novartis , Annexin Pharmaceuticals , Gene Signal , Ocular Therapeutics , and Asclepix Therapeutics along with other pharma companies are investigating their candidates proactively in a quest to launch their therapies as soon as possible in the Retinal vein occlusion market.

Marketing 52

Marketing Pharma Companies Drug Delivery Clinical Trials 52